EARLY lung function decline may help predict progression in patients at risk of systemic sclerosis, according to new longitudinal data.
Early Lung Changes Signal Disease Progression
Emerging evidence suggests that subtle lung abnormalities may reflect early disease activity in patients with very early systemic sclerosis. In a retrospective longitudinal analysis, researchers followed 73 at risk patients over a median of five years to determine whether baseline changes could predict progression to established disease.
The findings point to lung function as an early indicator of systemic sclerosis evolution rather than an isolated respiratory issue. Patients who progressed consistently showed lower baseline values, with a threshold below 70% strongly associated with increased risk over time. This positions early lung changes as a measurable extension of underlying autoimmune activity, even before classic clinical features fully emerge.
Disease Progression in At-Risk Patients
Only 12% of patients transitioned to systemic sclerosis during follow up, but those who did shared key rheumatologic features. All progressors were positive for disease specific antibodies and had evidence of early vascular changes, alongside reduced baseline lung function. Time to progression was also shorter in this group, reinforcing the link between early physiological changes and systemic disease evolution.
Importantly, even patients who remained clinically stable demonstrated gradual declines over time. This suggests that systemic sclerosis may continue to evolve beneath the surface, with organ level involvement occurring before formal classification criteria are met.
These findings challenge the assumption that stable patients are truly static, highlighting instead a continuum of disease activity that may not be immediately visible through traditional clinical markers alone.
Implications for Monitoring and Risk Stratification
Further analysis confirmed that autoimmune markers and capillaroscopic patterns were the strongest predictors of progression. However, lung function added an important layer of insight when combined with these established indicators.
Rather than viewing pulmonary testing as purely respiratory assessment, the data supports its role as part of a broader rheumatologic evaluation. Tracking subtle changes over time may help identify higher risk patients earlier and refine monitoring strategies.
Reference
Capparelli E et al. Pulmonary function decline in very early diagnosis of systemic sclerosis: A retrospective longitudinal single-center study. ACR Open Rheumatology. 2026;DOI:10.1002/acr2.90022.
Featured Image: Trsakaoe on Adobe Stock.
